Low-dose desferrioxamine test for the diagnosis of aluminium-related bone disease in patients on regular haemodialysis.
Bone biopsy in an invasive method of diagnosing aluminium related bone disease (ABD). Toxic side-effects have been reported with the currently used 'high-dose Desferrioxamine (DFO) tests.' A low-dose DFO test was evaluated for the diagnosis of ABD in 28 symptomatic patients (13 male) on regular haemodialysis treatment. DFO 0.5 g diluted in 100 ml of 0.9% sodium chloride was given intravenously during the first 2 h of dialysis. Aluminium estimation before (t1) and 48 h after DFO challenge (t2) were made by DC plasma emission spectrometry. Following the DFO test bone biopsy was performed and the specimen stained for aluminium using soluchrome zurine. The DFO test was considered positive if the t2 concentration was 150 micrograms/l or treble the amount of t1. Nineteen patients (8 male) fell into this group and all except two had ABD. Of the nine remaining patients (5 male) who had a negative DFO test none had ABD. We conclude that ABD can be diagnosed safely in the majority of patients using a low-dose DFO test, thereby avoiding toxic side-effects.
Department of Renal Medicine, Royal Liverpool/Sefton General Hospital, UK.
M
M
Yaqoob
R
R
Ahmad
N
N
Roberts
T
T
Helliwell
D000328:Adult; D000535:Aluminum / Q000009:adverse effects* / Q000097:blood; D001847:Bone Diseases / Q000175:diagnosis* / Q000209:etiology; D003676:Deferoxamine / Q000008:administration & dosage; D003951:Diagnostic Errors; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
D000535:Aluminum; D003676:Deferoxamine